Analyst Stance On Two Stocks: Zosano Pharma Corporation (ZSAN), Titan Pharmaceuticals, Inc. (TTNP)

The recently concluded session had traders exchanging Zosano Pharma Corporation (NASDAQ:ZSAN) high level. Roughly 1.21 million shares changed hands compared to the three-month volume average 0.8 million shares. The first trade took place at $0.619 and the stock went up 6.37% to attain the closing price of $0.67.

Zosano Pharma Corporation (ZSAN) Analyst Opinion

Zosano Pharma Corporation has a consensus outperform rating from 1 Wall Street analysts, and the number of shares currently sold short amount to at least 12.87% of shares outstanding. The stock spiked 16.02% last month and is down -14.1 this year. Wall Street is only getting more bullish on the stock, with 1 of analysts who cover ZSAN having a buy-equivalent rating. Analysts have placed a $4 price target on Zosano Pharma Corporation, suggesting a 497.01% gain from recent close. It’s currently trading about -81.07% below its 52-week high.

Zosano Pharma Corporation (NASDAQ:ZSAN) Intraday View

This stock (ZSAN) is ahead of its 52-week low with 20.72%. Its last month’s stock price volatility remained 8.36% which for the week stands at 9.1%. The share price has moved forward from its 20 days moving average, trading at a distance of 7.27% and stays -8.26% away from its 50 days moving average. Over the last five days, shares have managed 17.34% gains and now is down -44.6% since hitting its 200-day moving average of $1. Zosano Pharma Corporation (ZSAN) has made its way to a 12-month decline of -27.17%.

Turning to Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), its shares were trading at $1.25 a retreat of $-0.1, on the trading floor. The stock, after opening at $1.35, touched a high of $1.355 before paring much of its gains. So far, analysts are sticking with their bearish recommendations with the consensus call at 3. Titan Pharmaceuticals, Inc. has 0 buy ratings, 1 holds and 0 sells even after the stock tumbled -73.96% from its high of $4.80 to a $28.36 million market value through last close.

Titan Pharmaceuticals, Inc. (TTNP) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 3 to 3 during a month. Analysts set a 12-month price target of $2 a share. The target implies a 60% spike from where the shares are currently trading. Also, the current price highlights a discount of 60% to analysts’ high consensus price target.

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Intraday Trading

The counter witnessed a trading volume of 0.33 million shares versus an average volume of 0.22 million shares during last trading session. Its last month’s stock price volatility remained 7.16% which for the week approaches 7.13%. The lowest price the stock reached in the last trading day was $1.2 and compares with the $1.30 52-week low. The stock recovered -3.85% since its low point and has performed -68.75% year-to-date.

Previous articleAnalyst Commentary On Rennova Health, Inc. (RNVA), Sea Limited (SE)
Next articleAnalysts Shared Their Read on 2 Stocks: Sophiris Bio, Inc. (SPHS), Globus Maritime Limited (GLBS)